Response to Letter: “Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline”
Open accessThe DOI matches its Crossref record.
Abstract
We thank the authors of this letter to the editor for their positive comments about our guidelines and the important points they have raised. They refer to the poor record of enrollment in treatment programs of families and children affected by pediatric obesity and to similarly disheartening statistics on the attrition of those who actually make it to the enrollment stage. These two factors highlight the difficulty of successful treatment of pediatric obesity once developed and led us to emphasize the primary importance of prevention of obesity. The infrastructure in which a child lives affects a family’s ability to purchase the fruits and vegetables that we recommend and determines whether a child can safely achieve adequate moderate to vigorous physical activity during his or her play activities, which we endorse. Although clinicians can diagnose overweight and obesity, screen for comorbidities, and offer support and a range of measures to address problems within the confines of a clinical office, the child’s environment is the proximal driver of the development of obesity in most individuals. Providers of child health must support community-wide efforts to establish healthy environments to most effectively address the etiology of childhood obesity. The valuable points that the authors of this letter raised dovetail into the unmet needs we proposed in our closing section: Continued investigations into the most effective methods of preventing and treating obesity and into methods for changing environmental and economic factors that will lead to worldwide cultural changes in diet and activity should be priorities. Financial Disclosures of the Task Force*: D.M.S. (Chair)—Financial and Business/Organizational Interests: Zafgen [Biomedical Research; Investigator (grant)]; Significant Financial Interest or Leadership Position: Teva, Bristol-Myers, Organovo (Ownership Interests). S.A.A.—Financial and Business/Organizational Interests: Aegerion (Consultant), Boehringer Ingelheim (Advisory Board and Data Safety Monitoring), Bristol-Myers Squibb (Advisory Board), INTARCIA Therapeutics, Inc. (Consultant), Lilly USA, LLC (Advisory Board), Novo Nordisk (Advisory Board), Ranbaxy (Consultant), Sanofi-aventis (Advisory Board), Janssen Pharmaceutical (Principal Investigator), NIH (Grantee and Reviewer); Significant Financial Interest or Leadership Position: Aegerion (Consultant), Boehringer Ingelheim (Advisory Board & Data Safety Monitoring), Bristol-Myers Squibb (Advisory Board), INTARCIA Therapeutics, Inc. (Consultant), Lilly USA, LLC (Advisory Board), Novo Nordisk (Advisory Board), Ranbaxy (Consultant), Sanofi-aventis (Advisory Board), Janssen Pharmaceutical (Principal Investigator), NIH (Grantee and Reviewer). E.L.C.—Financial and Business/Organizational Interests: Pediatric Endocrine Society (Obesity Committee Chair); Significant Financial Interest or Leadership Position: none declared. I.S.F.—Financial and Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: none declared. M.H.M.†—Financial and Business/Organizational Interests: Mayo Clinic, Evidence-Based Practice Center; Significant Financial Interest or Leadership Position: none declared. J.H.S.—Financial and Business/Organizational Interests: Pediatric Endocrine Society (Chair, MOC Committee; Member, SCAMPS Committee), Daiichi Sankyo [Clinical Trial (funds to UF)], Sanofi [Clinical Trail (funds to UF)]; Significant Financial Interest or Leadership Position: Daiichi Sankyo [Clinical Trial (funds to UF)], Sanofi (Clinical Trial to UF). J.A.Y—Financial and Business/Organizational Interests: Zafgen Inc. [Principal Investigator (funds to NIH)]; Significant Financial Interest or Leadership Position: Zafgen Inc. [Principal Investigator (funds to NIH)]. *Financial, business, and organizational disclosures of the Task Force cover the year before publication. Disclosures before this time period are archived. †Evidence-based reviews for this guideline were prepared by the Mayo Clinic, Evidence-based Practice Center, under contract with the Endocrine Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Self-citationKim, J. H., Yun, S., Hwang, S.-S., Shim, J. O., Chae, H. W., Lee, Y. J., Lee, J. H., Kim, S. C., Lim, D., Yang, S. W., et al. (2018) · Korean Journal of Pediatrics · doi:10.3345/kjp.2018.61.5.135 · Cited by 638
de Ferranti, S. D., Steinberger, J., Ameduri, R., Baker, A., Gooding, H., Kelly, A. S., Mietus-Snyder, M., Mitsnefes, M. M., Peterson, A. L., St-Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 441
Seo, J.-Y., & Kim, J. H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186050 · Cited by 38
Zemel, M. B., Kolterman, O., Rinella, M., Vuppalanchi, R., Flores, O., Barritt, A. S., Siddiqui, M., & Chalasani, N. (2019) · Obesity · doi:10.1002/oby.22346 · Cited by 19
Metadata
- Authors
- Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-06-01
- Volume
- 102
- Issue
- 6
- Pages
- 2123-2124
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2623359667
- Cited by
- 138
- References
- 0
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to Letter: “Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline”. https://app.cochat.ai/papers/10.1210/jc.2017-00561
- The paper
- Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017). Response to Letter: “Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline”. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2017-00561
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.